Navigation Links
Halozyme's Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
Date:6/24/2011

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced final results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog®, reduces the variability of insulin absorption and reduces post-meal glycemic excursions compared to NovoLog alone. Halozyme is presenting these findings in a late-breaking poster titled: "Addition of Human Hyaluronidase to Rapid Analog Insulin Reduces the Absolute Variability of Early Insulin Absorption across Infusion Set Life" at the American Diabetes Association 71st Scientific Sessions on Sunday, June 26 in San Diego.  

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"These additional results from Halozyme's first pump study demonstrate that the faster pharmacokinetic and glucodynamic findings are significantly more consistent and less variable for the Aspart-PH20 combination than for NovoLog alone in the pump setting," stated Doug Muchmore, M.D., vice president of endocrinology clinical development at Halozyme. "More consistent and rapid insulin absorption over the life of the infusion set with the addition of rHuPH20 may help patients using insulin pumps achieve tighter glucose control, better manage their disease and obtain improved outcomes."

The double-blind crossover design Phase 1 clinical trial compared Aspart-PH20 to as
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
2. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
3. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
4. Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
5. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
6. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
7. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
8. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
9. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
10. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
11. Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Decision Resources ... multiple sclerosis (MS) patients currently treated with ... have ever experienced flushing and/or gastrointestinal events ... patients are currently experiencing these side effects, ... effective medical management of such events. In ...
(Date:7/22/2014)... 2014 Research and Markets  has announced ... report to their offering. ... to diagnose, monitor, and assess medical conditions, diseases, or ... outcomes for earlier and more targeted treatment. These tests ... accurate results. This kind of diagnostics provides early detection ...
(Date:7/22/2014)... July 22, 2014  Eyeon Therapeutics has received a ... based on a charged hydrophilic polymer developed at Particles ... been shown to be safe and effective in a ... CEO states, "This first set of claims around the ... to moving this technology into the commercial phase.  We ...
Breaking Medicine Technology:Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
... MonoSol Rx, the developers of PharmFilm® technology and ... film products, today announced that it held a ... Food and Drug Administration (FDA) regarding the development ... a 505(b)(2) pathway.  The registration dossier of Montelukast ...
... 2011 PTC Therapeutics, Inc. (PTC) today announced the ... Medical Officer.  Dr. Spiegel served previously as Chief Medical ... of Jay Barth, M.D. to Vice President of Clinical ... Spiegel will report to Stuart W. Peltz, Ph.D., President ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3
(Date:7/22/2014)... Plate Club you eat pretty much everything you put ... Cornell University study shows that the average adult eats 92% ... plate. "If you put it on your plate, ... of the forthcoming book, Slim by Design, Professor of Marketing ... Wansink and co-author Katherine Abowd Johnson analyzed 1179 diners and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Legislation ... Seniors Access to Local Pharmacies Act of 2014”) ... Part D would undermine the availability of lower ... by $21 billion over the next 10 years, ... released by the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... New Rochelle, NY -- New guidelines on cholesterol treatment ... least double the risk of dying from atherosclerotic cardiovascular ... as do women with a similar risk profile (based ... levels). The implications of this finding for when and ... an Editorial in Journal of Men,s Health , ...
(Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
(Date:7/22/2014)... News) -- One of the largest studies ever conducted ... uncovered 83 new sites on chromosomes that harbor inherited ... an international team of researchers, now bring the total ... to 108. Although these schizophrenia-associated genes aren,t ... predict who will or will not develop the illness, ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... Edward G.,Rendell today issued an executive order regarding ... closed after the law,authorizing its operation expired on ... 2003, when PHC4 was allowed to "sunset",by the ... action., The Rendell administration is committed to ...
... Illinois at Chicago is one of 11 centers in ... in the Clinical Islet Transplant Consortium funded by the ... clinical studies to test new approaches to islet transplantation ... effects for adults with difficult-to-control type 1 diabetes. , ...
... to vote soon on legislation that would cut ... WASHINGTON, July 8 Seniors across,Pennsylvania are speaking ... in legislation being considered in the U.S. Senate. ... the Medicare Advantage,program in Pennsylvania alone and severely ...
... DETROIT, July 8 The Barbara Ann Karmanos,Cancer ... with Meadowbrook C,Management, LLC, to lease space and ... Michigan. The approximately 14,000 square foot,space will allow ... in Novi,and the surrounding communities, as well as ...
... cancer research, particularly in observational epidemiology studies. The ... mitigated if researchers use more exacting standards when ... in the July 8 online issue of the ... Additionally, the impact of false-positive results could be ...
... in Iron Blood Levels Associated with Decreased Cancer Risk in ... arterial disease who participated in a randomized controlled trial in ... a reduced incidence of cancer relative to men in the ... have suggested that lower levels of iron in the blood ...
Cached Medicine News:Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:Pennsylvania Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services 2Health News:Awareness of epidemiology's limitations could reduce impact of false-positive cancer results 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4
Standard vice clamp, can be fitted instead of Quick Realease Cassette...
Knife sharpening kit...
... work, it is necessary to cool a specimen ... be fitted to most microtomes and will permit ... depending on conditions. The equipment consists of a ... stage is best suited for operation with a ...
... some sectioning work, it is necessary to cool ... Freezer can be fitted to most microtomes and ... or lower, depending on conditions. The equipment consists ... The cooling stage is best suited for operation ...
Medicine Products: